Innoviva (INVA)
(Delayed Data from NSDQ)
$19.69 USD
+0.17 (0.87%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $19.67 -0.02 (-0.10%) 5:32 PM ET
4-Sell of 5 4
B Value D Growth C Momentum C VGM
Industry / Sector Report
Industry : Large Cap Pharmaceuticals
Zacks Industry Rank
Top 24% (61 out of 251)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.00 | 1.98 | 9.99 |
Current Quarter Estimate | NA | 37.53 | 61.00 |
Year Ago Quarter Estimate | 0.98 | 12.41 | 54.84 |
Next Quarter Estimate | NA | 38.15 | 63.00 |
Next Year Estimate | NA | 172.65 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -77.78 | 6.40 | 15.67 |
Next Year | NA | 16.50 | 11.34 |
Last 5 Years | 1.90 | 2.90 | 8.10 |
Next 5 Years | NA | 11.60 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 6.78 | 22.60 |
Price/Book (MRQ) | 1.84 | 6.38 |
Price/Cash Flow (MRFY) | 5.58 | 12.28 |
Dividend Yield | 0.00% | 2.01% |
Net Profit Margin (TTM) | 44.00% | 18.86% |
Return on Equity (TTM) | 33.26% | 34.56% |
Debt to Equity (MRQ) | 0.67 | 40.19 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.